We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
HUYA Announces Strategic Alliance with Abbott on Drug and Biomarker Development Candidates
News

HUYA Announces Strategic Alliance with Abbott on Drug and Biomarker Development Candidates

HUYA Announces Strategic Alliance with Abbott on Drug and Biomarker Development Candidates
News

HUYA Announces Strategic Alliance with Abbott on Drug and Biomarker Development Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "HUYA Announces Strategic Alliance with Abbott on Drug and Biomarker Development Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HUYA Bioscience International has announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.

Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.

"China has an extremely rich pool of drug candidates, which we are able to tap through our extensive network of partners," said Mireille Gingras, PhD, President and CEO of HUYA. "We've been effective in leveraging those relationships to the mutual benefit of our partners in the West and in China, and we're looking forward to a productive collaboration with Abbott."

HUYA's model is based on long-term relationships with its Chinese partners and this provides a continuous source of compounds, unlike a single compound strategy. Once a compound is licensed, the ongoing exchange of expertise and data lowers risk and facilitates clinical development in both China and the West.

HUYA currently has two clinical stage drugs licensed from China in the therapeutic areas of Cardiovascular and Oncology for development in the West.
Advertisement